LONDON, April 23, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:
Computer diagnostics could offer opportunity for clinical laboratory professionals to add value to clinicians in diagnosing diseases. IT companies in collaboration with test vendors are developing computer software that complements the skills of human test interpretation.
This report, Bioinformatics in IVD Testing looks at the various IVD market segments where bionformatics is expected to have the most impact.
Bioinformatics-based testing has made a huge contribution to cancer diagnosis and therapy management. In infectious disease diagnostics it allows the detection of difficult to culture pathogenic bacteria or viruses and to uncover the epidemiology of infections. The bioinformatic analysis of mutations of known human genes is used to diagnose common disorders, inherited diseases, or different types of cancer and can indicate the prognosis of malignant diseases.
What developments are driving this trend? What are labs and providers doing to incorporate these products into practice? And how are payors and regulators reacting? Who is partnering with who to deliver a solid combination product? This report delves into these issues and provides an excellent round-up of the current status of bioinformatics in the IVD industry.
As part of its coverage, the report provides information on the following developments:
• Selected Diagnostic Tests That Incorporate Bioinformatics
• Selected Multiplexed Tissue-Based Cancer Tests
• Selected Histology Analyses Software Tools
• Selected Blood-Based Cancer Biomarker Tests That Use Software Analysis Tools
• Selected Chronic Diseases Tests With Integrated Bioinformatics
• Selected Innovations in Bioinformatic-Based Tests For Psychiatric Disorders
• Selected Systems For Bioinformatics-Based Infectious Disease Testing
• Selected Next Generation Sequencing Platforms
The report discusses tests and technologies that are currently available and those that are expected to take their place. Generally, current products and technologies establish the standard of care and its value to payers. Many of the assays and techniques presented in the report are expected to replace the standard of care in 2013, but with healthcare systems' emphasis on cost/benefit analysis for new technologies adoption, the market value and thus penetration capabilities of newer approaches may be limited.
The report looks at the bioinformatics-based product offerings and developments of the following companies, among others:
• RocheAffymetrix Inc.
• AssureRx Health, Inc.
• Bio-Reference Laboratories, Inc. (BRLI)
• Dako A/S
• Thermo Fisher
• Medtronic Inc.
• PerkinElmer, Inc.
• Prometheus Labs
• QIAGEN N.V.
CHAPTER ONE: EXECUTIVE SUMMARY
Scope and Methodology
IVD Markets Most Affected by Bioinformatics
Advances in Lab Medicine
CHAPTER TWO: INTRODUCTION
The Case for Bioinformatics
CHAPTER THREE: ENABLING TECHNOLOGIES AND COMMERCIALIZATION ARRANGEMENTS
Alliances and Collaborations
Advances in Clinical Bioinformatics
Reimbursement-Driven Health Data Analytics
Insurers, PBMs and Providers
The Interface and Test Technologies
Bioinformatics for Consumers
CHAPTER FOUR: MARKET ANALYSIS – BIOINFORMATICS-BASED DIAGNOSTICS
The Commercial Outlook
Trends In Bioinformatics-Based Tests For Cancer
Trends in Bioinformatics-based Tests for Diabetes
Trends in Bioinformatics-based Tests for Cardiovascular Disease
Trends in Bioinformatics-based Tests for Chronic Diseases
Trends In Bioinformatics-Based Tests In Microbiology
Trends in Bioinformatics-based Diagnostics for Prenatal Studies
The Commercial Outlook
CHAPTER FIVE: CONCLUSION
CHAPTER SIX: IVD COMPANIES AND BIOINFORMATIC-BASED OFFERINGS
Aperio Technologies, Inc.
Arrayit Diagnostics Inc.
AssureRx Health, Inc.
Atossa Genetics, Inc.
BG Medicine, Inc.
Bio-Reference Laboratories, Inc. (BRLI)
Breath Testing at Home
Children's Hospital of Philadelphia:
Chronix Biomedical Inc.
CombiMatrix Molecular Diagnostics, Inc.
Crescendo Bioscience, Inc.
deCode genetics ehf
Duke University Medical Center
Everist Genomics, Inc. (EGI)
Foundation Medicine. Inc
Genomic Health, Inc.
Health Discovery Corporation (HDC)
Massachusetts Institute of Technology
Mayo Medical Laboratories
One Lambda, Inc.
Oregon Health & Science University (OHSU)
Prometheus Laboratories Inc.
Tethys Bioscience Inc.
University of Houston
XDx Inc. – Expression Diagnostics
CHAPTER SEVEN: COMPANY PROFILES: INFORMATION TECHNOLOGY SPECIALISTS
CollabRx, Inc. (formerly Tegal Corp)
Signature Mapping Medical Sciences, Inc.
Silicon Valley Biosystems (SV Bio)
LIST OF EXHIBITS
CHAPTER ONE: EXECUTIVE SUMMARY
Table 1-1: Selected Salient Developments For Now And The Future
Table 1-1: IVD Segments Potentially Most Affected By Bioinformatics-Based Tests
CHAPTER TWO: ENABLING TECHNOLOGIES AND COMMERCIALIZATION ARRANGEMENTS
Table 3-1: Selected Collaborations For Bioinformatics-Based Diagnostics
Table 3-2: Selected Open-Source Variant Annotation Software
Table 3-3: Selected Information Technology Innovations In Clinical Diagnostics
CHAPTER THREE: MARKET ANALYSIS – BIOINFORMATICS-BASED DIAGNOSTICS
Table 4-1: Selected Diagnostic Tests That Incorporate Bioinformatics
Table 4-2: Selected Multiplexed Tissue-Based Cancer Tests
Table 4-3: Selected Histology Analyses Software Tools
Table 4-4: Selected Blood-Based Cancer Biomarker Tests That Use Software Analysis Tools
Table 4-5: Selected Innovations In Bioinformatic-Based Tests For CVD
Table 4-6: Selected Chronic Diseases Tests With Integrated Bioinformatics
Table 4-7: Selected Innovations In Bioinformatic-Based Tests
For Psychiatric Disorders
Table 4-8: Selected Systems For Bioinformatics-Based Infectious Disease Testing
Table 4-9: Selected Next Generation Sequencing Platforms
Table 4-10: Ivd Segments Potentially Most Affected By Bioinformatics-Based Tests